Man Group
OCUL icon

Man Group’s Ocular Therapeutix OCUL Stock Holding History

Man Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.34M Buy
543,582
+366,114
+206% +$3.32M 0.01% 1106
2026
Q1 		$1.5M Buy
177,468
+131,379
+285% +$1.25M ﹤0.01% 1681
2025
Q4 		$560K Buy
+46,089
New +$560K ﹤0.01% 1863
2024
Q2 		– Sell
-21,543
Closed -$196K – 2196
2024
Q1 		$196K Buy
+21,543
New +$153K ﹤0.01% 2013
2023
Q3 		– Hold
0
– – – 1865
2022
Q1 		– Sell
-106,970
Closed -$746K – 2303
2021
Q4 		$746K Buy
+106,970
New +$831K ﹤0.01% 1413
2020
Q1 		– Sell
-760,490
Closed -$3M – 1805
2019
Q4 		$3M Sell
760,490
-1,148,988
-60% -$3.99M 0.01% 1191
2019
Q3 		$5.8M Sell
1,909,478
-248,671
-12% -$1.11M 0.02% 808
2019
Q2 		$9.5M Buy
2,158,149
+434,693
+25% +$1.61M 0.03% 653
2019
Q1 		$6.84M Buy
1,723,456
+535,948
+45% +$2.15M 0.03% 751
2018
Q4 		$4.73M Buy
1,187,508
+684,391
+136% +$3.77M 0.02% 797
2018
Q3 		$3.46M Buy
+503,117
New +$3.16M 0.01% 1189

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Man Group's OCUL Position: Q2 2026 in Review

Man Group increased its Ocular Therapeutix (OCUL) stake by 206% in Q2 2026, buying an estimated $3.32M and bringing the position to 543,582 shares worth $5.34M. The position accounts for 0.01% of the portfolio, ranked #1106.

Man Group first reported a position in OCUL in Q3 2018 and has held it in 11 quarters since. The position peaked at $9.5M in Q2 2019. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Man Group held 543,582 shares of Ocular Therapeutix worth $5.34M as of Q2 2026.
  • Man Group bought 366,114 Ocular Therapeutix shares in Q2 2026, an estimated $3.32M.
  • Ocular Therapeutix made up 0.01% of Man Group's portfolio in Q2 2026, its #1106 holding.
  • Man Group first reported a position in Ocular Therapeutix in Q3 2018 and has held it in 11 quarters since.
  • Man Group's Ocular Therapeutix position peaked at $9.5M in Q2 2019.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.